Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2015 / Cilt: 21 - Sayı: 1

Mastalgia Assesment and Hormonal Correlations in Patients with Polycystic Ovary Syndrome

Pages
18–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It seems that in mastalgia positive PCOS group, age and BMI effects the frequency of mastalgia but we can\'t say the same for hormones.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The aim of this study is the assesment of relationship between mastalgia and hormonal parameters and frequency of mastalgia in polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:STUDY DESIGN: 141 patients who are admitted to our clinic were included in this study after taking their informed consent. 78 patients who were diagnosed as PCOS according to the Rotterdam Criteria constitute the patient group. 63 patients who are admitted for routine control and had no hormonal pathology constitute the control group.
💡
Conclusion & Impact:It seems that in mastalgia positive PCOS group, age and BMI effects the frequency of mastalgia but we can\'t say the same for hormones.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The aim of this study is the assesment of relationship between mastalgia and hormonal parameters and frequency of mastalgia in polycystic ovary syndrome (PCOS). STUDY DESIGN: 141 patients who are admitted to our clinic were included in this study after taking their informed consent. 78 patients who were diagnosed as PCOS according to the Rotterdam Criteria constitute the patient group. 63 patients who are admitted for routine control and had no hormonal pathology constitute the control group. Age of the patients were noted, complaints of mastalgia were questioned and hormonal parameters (Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Testosterone, Dehydroepiandrosterone Sulphate (DHEAS), Thyroid-Stimulating Hormone (TSH), Body Mass Index (BMI)) were recorded. RESULTS: Frequency of mastalgia was found as 24.4% in PCOS group and 33.3% in control group and there is no statistical difference (p>0.05). It is apparent that the PCOS group, when compared with the control group, is characterized by higher LH levels and higher Testosterone, DHEAS and TSH levels (p<0.001, p<0.001, p=0.019, p=0.04) CONCLUSION: Although there were different LH and Testosterone levels, we couldn\'t find statistical dif- ference for the frequency of mastalgia between PCOS and the control group. There were no relation- ship between age, BMI and hormonal parameters in patients with mastalgia, so PCOS couldn\'t be a fac- tor that effects the frequency of mastalgia. It seems that in mastalgia positive PCOS group, age and BMI effects the frequency of mastalgia but we can\'t say the same for hormones.

Özet

AMAÇ: Kadınlar arasından yaygın görülen bir durum olan mas taljinin polikistik over (PCOS) hastalığında görülme sıklığı ve hormonal parametreler ile ilişkisini araştırmaktır. GEREÇ VE YÖNTEM: Polikiniğimize başvuran hastalardan çalışmaya katılmayı gönüllü olarak kabul eden 141 kişi dahil edildi. Rotterdam kriterlerine göre PCOS tanısı alan 78 kişi, hasta grubunu oluşturmakta idi. Polikliniğimize genel muayene için başvuran ve ek bir hormonal patoloji saptanmayan 63 has- ta kontrol grubunu oluşturmakta idi. Bu hastalarda yaş, vücut kitle indeksi, hormonal parametreler (FSH, LH, Estradiol, Testosteron, Dehidroepiandesteron sülfat (DHEASO4), Tiroid stimülan hormon (TSH)) değerlendirildi ve mastalji şikayetleri sorgulandı. BULGULAR: Çalışmaya katılan PCOS grubunda ortalama mastalji görülme sıklığı %24.4. Kontrol grubunda bu oran %33.3 (p>0.05). Her iki grup arasında LH ve testosterone, DHEASO 4 ve TSH düzeyleri açısından anlamlı fark olduğu bu- lundu (p<0,001, p<0,001, p=0,01, p=0,04)). SONUÇ: Çalışmamızda PCOS grubunda, kontrol grubundan farklı LH ve Tetosteron düzeyleri olmasına rağmen mastalji gö- rülme sıklığı açısından anlamlı fark yoktur. Mastaljisi olanlarda yaş, BMI ve hormonal parametreler açısından ilişki yoktur yani PCOS, mastalji sıklığını etkileyen özel bir belirleyici değildir.Mastaljiyi hormonlar etkilemiyor ancak ileri yaş ve BMI arttıkça mastalji görülme sıklığı artıyor gözükmektedir.

🔖

Cite This Article

KIYAK, E. Ç., SEÇKİN, L., GÖÇMEN, A. Y., OKUR, A., ARSLAN, E., SERİN, H. İ., ÇAĞLAYAN, K., ENGİN, Y. Ü. (2015). Mastalgia Assesment and Hormonal Correlations in Patients with Polycystic Ovary Syndrome. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 21 - Sayı: 1, 18–21. https://ajindex.com/articles/226998

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Petraglia F. Hormone-dependent gynaecological disor- ders: a pathophysiological perspective for appropriate treatment. Best Pract Res Clin Obstet Gynaecol 2008;22 (2):235-49
  2. Adali E, Kolusari A, Adali F, Yildizhan R, Kurdoglu M, Sahin HG. Doppler analysis of uterine perfusion and ovar- ian stromal blood flow in polycystic ovary syndrome. Int J Gynaecol Obstet 2009;105:154-7
  3. Goodarzi MO. Azziz R. Diagnosis, epidemiology, and ge- netics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006;20(2):193-205
  4. Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Lipids in polycystic ovary syndrome: Role of hyperin- sulinemia and effects of metformin. Am J Obstet Gynecol 2006;194 (5):1266-72
  5. Duleba AJ. Medical management of metabolic dysfunc- tion in PCOS. Steroids 2012;77(4):306-11
  6. Sharma ST, Nestler JE. Prevention of diabetes and car- diovascular disease in women with PCOS: Treatment withinsulin sensitizers. Best Pract Res Clin Endocrinol Metab 2006;20(2):245-60
  7. Aydin Y, Atis A, Kaleli S, Uludag S, Goker N. Cabergoline versus bromocriptine for symptomatic treatment of pre- menstrual mastalgia: a randomised, open-label study. Eur J Obstet Gynecol Reprod Biol 2010;150 (2):203-6
  8. Qureshi S, Sultan N. Topical nonsteroidal antiinflamma- tory drugs versusoil of evening primrose in thetreatment of mastalgia. Surgeon 2005;3(1):7-10
  9. S. Qureshi, N. Sultan Topical nonsteroidal antiinflamma- tory drugs versus oil of evening primrose in the treatment of mastalgia Surgeon 2005;3(1):7-10
  10. Pollitt J, Twine C, Gateley CA. Benign breast disease. Women’s Health Medicine 2006;3(1):1-4
  11. Mansel RE, Goyal A, Preece P, Leinster S, Maddox PR, Gateley C, Kubista E, Fournier DV. European randomized, multicenter study of goserelin (Zoladex) in the man- agement of mastalgia American Journal of Obstetrics and Gynecology 2004;191:1942-9
  12. Druckmann R. Progestins and their effects on the breast. Maturitas 2003;46:59-69
  13. Genc V, Genc A, Ustuner E, Dusunceli EB, Oztuna D, Bayar S, Kurtais Y. Is there an association between mastalgia and fibromyalgia? Comparing prevalence and symptom severity. The Breast 2011;20:314-18
  14. Rosolowich V, Saettler E, Szuck B. Mastalgia JOGC 2006; 170:49-57
  15. Yüksekkaya R, Çelikyay F, Voyvoda N, Gökdemir Ö. Breast ultrasound findings in patıents wıth mastalgıa under the age of fourty. The Journal of Breast Health 2012;8 (1):19-22
  16. Balen A. The pathophysiology of polycystic ovary syn- drome